Abstracts tagged "Systemic sclerosis"

Abstract Number: 1867 • ACR Convergence 2025
Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics
Laura Much¹, Elena Pachera², Havard Fretheim³, Knut EA Lundin⁴, Lumeng Li⁵, Astrid Hofman⁶, Pietro Bearzi⁵, Philip Stauffer¹, Michael Scharl⁷, Oyvind Molberg⁸, Oliver Distler⁹ and Anna-Maria Hoffmann-Vold³, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Oslo, Norway, ⁴Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ⁶Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Oslo University Hospital, Oslo, Nepal, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: SSc frequently results in serious gastrointestinal (GI) complications that contribute to increased morbidity and mortality. Understanding the molecular changes across different disease stages is…
Abstract Number: 1580 • ACR Convergence 2025
Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Gesa Sauer⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Muriel Elhai⁷, Carina Mihai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital zurich, Zürich, Switzerland, ⁸University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is highly prevalent in systemic sclerosis (SSc) and a leading cause of mortality. Recent studies have identified clinical risk factors…
Abstract Number: 1199 • ACR Convergence 2025
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
Darya S. Jalaledin¹, Aidan pye², Angela Chang², Navid Saleh², Saud AlHajeri³, Beatrice Daviault⁴, Arusa Shah⁵, Sabrina Hoa⁶, Océane Landon-Cardinal⁷, Alec Yu², Robert Levy⁸, Jennifer Wilson⁹, Charles Poirier⁴, James Choi², John Yee², Hyein Kim² and Kun Huang¹⁰, ¹Université de Montréal, Saint-Lambert, QC, Canada, ²University of British Columbia, VANCOUVER, BC, Canada, ³University of British Columbia, Vancouver, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹UBC, Vancouver, BC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…
Abstract Number: 0963 • ACR Convergence 2025
Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
Vanessa Smith¹, Stefano Soldano², Rosanna Campitiello³, Emanuele Gotelli³, Paola Montagna⁴, Tamara Vojinovic⁴, Sabrina Paolino², Carmen Pizzorni², Alberto Sulli² and Maurizio Cutolo⁵, ¹Ghent University Hospital, Gent, Belgium, ²University of Genoa, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genoa, Genova, ⁵University of Genova, Genova, Italy
Background/Purpose: In the complex pathogenesis of systemic sclerosis (SSc), macrophages are mainly involved in mechanism of progressive tissue fibrosis of skin and internal organs, particularly…
Abstract Number: 0693 • ACR Convergence 2025
Impact of X Chromosome Dosage on the Development of Diffuse and Limited Systemic Sclerosis in Klinefelter, Triple X, and Turner Syndromes: A Multicenter Cohort Study
Hanieh Akbari¹, Anna-Kay Palmer² and Irene Tan³, ¹Jefferson Einstein Montgomery Medical Center, Norristown, PA, ²Jefferson Einstein Philadelphia Hospital, Department of Internal Medicine, Philadelphia, PA, ³Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Diffuse and limited systemic sclerosis (SSc) are autoimmune connective tissue diseases with a strong female predominance, suggesting a potential role for X chromosome dosage…
Abstract Number: 0671 • ACR Convergence 2025
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort
Francesca Romana Di Ciommo¹, Ashish Balar², Subhash Kulkarni³, Aidan K Strother², Michael Hughes⁴, Brian Skaug⁵, Maureen Mayes⁶, Shervin Assassi⁷, Ali Y Ayla² and Zsuzsanna McMahan⁸, ¹La Sapienza University of Rome, Rome, Italy, ²UTHealth Houston, Houston, TX, ³BIDMC, Boston, MA, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁸UT Health Houston, Houston, TX
Background/Purpose: Cardiac manifestations significantly impact the prognosis of patients with systemic sclerosis (SSc), underscoring the need for early risk stratification. While gastrointestinal (GI) symptoms are…
Abstract Number: 0224 • ACR Convergence 2025
Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
John Hickernell¹ and Zineb Aouhab², ¹Loyola Univeristy Medical Center, Chicago, IL, ²Loyola University Medical Center, Oak Brook, IL
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) reduces mortality. The American College of Radiology, European Society of Cardiology/European Respiratory…
Abstract Number: 2502 • ACR Convergence 2025
Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study
Santiago Dans Caballero¹, Rafaela Ortega-Castro², Chary López pedrera³, Alejandro Escudero⁴, Beatriz Vellón-García⁵, Carlos Pérez Sánchez⁶ and Clementina López Medina⁷, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, ⁵Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁷Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Systemic sclerosis (SSc) is a clinically and biologically heterogeneous autoimmune disease characterized by multiorgan involvement, substantial morbidity, and high mortality. Traditional classification systems (based…
Abstract Number: 2477 • ACR Convergence 2025
Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giacomo De Luca⁴, Giovanna Cuomo⁵, Lidia P Ananieva⁶, Eric Hachulla⁷, Vanessa Smith⁸, Ana Maria Gheorghiu⁹, Radim Bečvář¹⁰, Patricia E. Carreira¹¹, Nicolas Hunzelmann¹², Daniel Furst¹³, Vera Ortiz-Santamaria¹⁴, Francesco Del Galdo¹⁵, Marco Matucci-Cerinic¹⁶ and Anna-Maria Hoffmann-Vold¹⁷, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Italy, ⁵Department of Precision Medicine, University Hospital Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁶A Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷University of Lille, LILLE, France, ⁸Ghent University Hospital, Gent, Belgium, ⁹Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹⁰Department of Internal Medicine, Charles University,, Prague, Czech Republic, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, ¹³Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁴HOSP. GENERAL DE GRANOLLERS, Barcelona, Spain, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The therapeutic landscape for systemic sclerosis- interstitial lung disease (SSc-ILD) has rapidly evolved over the past decade, with increasing adoption of immunosuppressive (IST) and…
Abstract Number: 1866 • ACR Convergence 2025
Elucidating gastric pathology in systemic sclerosis using single-cell RNA sequencing
kristina clark¹, Moustafa Attar², Matthias Friedrich³, Charles Murray⁴, Alexander Clarke² and Christopher Denton⁵, ¹Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ²Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ³Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom, ⁴Royal Free Hospital NHS Trust, London, United Kingdom, ⁵University College London, UK, London, United Kingdom
Background/Purpose: Gastrointestinal (GI) involvement in systemic sclerosis (SSc) affects over 90% of patients and represents a large clinical burden and unmet need. Unlike the skin…
Abstract Number: 1577 • ACR Convergence 2025
Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Luc Mouthon¹, David Launay², Sylvie leroy³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Emmanuel Bergot⁶, Boris Bienvenu⁷, Benjamin Chaigne¹, Pascal Cohen⁸, Bruno Crestani⁹, Anca Corondan¹⁰, bertrand Dunogue¹, Christian Lavigne¹¹, Jonathan London¹², Jean-Marc Naccache¹⁰, Gabriel Baron¹³, Alexis REGENT¹⁴, Benjamin Terrier¹⁵, Zahir AMOURA¹⁶, Charles Marquette¹⁰ and Philippe Ravaud¹³, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ³AP HP, Paris, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Caen, France, ⁷Saint Joseph Hospital, Marseille, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁹CHU, Paris, France, ¹⁰NA, Paris, France, ¹¹CHU, Angers, France, ¹²Hôpital Croix-Saint-Simon, Paris, France, ¹³Hôtel-Dieu, Université Paris Cité,, Paris, France, ¹⁴Hopital Cochin, Paris, France, ¹⁵Cochin Hospital, Paris, France, ¹⁶APHP, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Randomized controlled trials favoured the use of cyclophosphamide…
Abstract Number: 1194 • ACR Convergence 2025
Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
Antonia Valenzuela¹, Nicolás González², José Rojas³, Martin Fuentes³, Srijana Davuluri⁴, Brian Lee⁵, David Fiorentino⁶ and Lorinda Chung⁴, ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ³Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ⁴Stanford University, Stanford, CA, ⁵Stanford University, Stanford, ⁶Department of Dermatology, Stanford University Medical Center, Stanford, CA
Background/Purpose: Calcinosis is a painful, debilitating manifestation in connective tissue diseases. Recent findings suggest a link between proton pump inhibitor (PPI) use and calcinosis in…
Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Dennis Bleck¹, Karen Drechsel², Tim Filla³, Yi-Nan Li⁴, Andrea-Hermina Györfi⁵, Alexandru-Emil Matei⁶ and Jörg Distler⁷, ¹University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital Düsseldorf, Department of Rheumatology, Hiller Research center, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…
Abstract Number: 0692 • ACR Convergence 2025
A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
Christopher Denton¹, Philip Yee², medha kanitkar³, Charlotte Clarke⁴, Saiam Ahmed⁴, Voon H. Ong³, Francesco Del Galdo⁵, John Pauling⁶, Marina Anderson⁷, Muditha Samaranayaka⁸, Michael Hughes⁹, Smita Bhat¹⁰, Bridget Griffiths¹¹, MAYA BUCH¹², David D'Cruz¹³, Ariane Herrick¹⁴, Madelon Vonk¹⁵, Nicholas Feemantle⁴ and Dehbi Hakim-Moulay⁴, ¹University College London, UK, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶North Bristol NHS Trust, Bristol, United Kingdom, ⁷Lancaster University and NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom, ⁸Salford Royal Hospital, Salford, United Kingdom, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁰Ninewells Hospital Dundee, Dundee, Scotland, United Kingdom, ¹¹Ninewells Hospital Dundee, Newcastle, England, United Kingdom, ¹²UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹³Kings College London, London, United Kingdom, ¹⁴The University of Manchester, UK, Aberdeen, United Kingdom, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Mycophenolate mofetil (MMF) is recommended for skin in diffuse cutaneous (dc)SSc, and for lung fibrosis in SSc, but patients with limited cutaneous (lc)SSc are…
Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].